Gilead Sciences, Inc.

Gilead Connecticut, Inc.

Cgi Pharmaceuticals, Inc.

Genentech, Inc.

Kronos Bio, Inc.

Genetech, Inc.

Peter A Blomgren

Kevin S Currie

Jeffrey E Kropf

Jianjun Xu

Scott A Mitchell

Seung H Lee

Zhongdong Zhao

Aaron C Schmitt

Jennifer R Lo

Douglas Gregory Stafford

Pavel E Zhichkin

Jin-Ming Xiong

Sundaramoorthi Swaminathan

Jayaraman Chandrasekhar

Kirk L Stevens

Christian Gege

Suet Chung Yeung

Julian Andrew Codelli

William John Watkins

Leena Patel

Christopher T Clark

Yasamin Moazami

Jason K Perry

Taryn Campbell

Nicole Nava

Natalie Seeger

Chandrasekar Venkataramani

Jennifer Anne Treiberg

Xiaojing Wang

Daniel Fred Ortwine

Wendy B Young

Zhimin Du

Stephane Perreault

Julie Farand

Kassandra F Sedillo

Antonio J M Barbosa

David R Brittelli

Honglu Zhang

Ravi Krishnamoorthy

David M Armistead

Musong Kim

Mihaela Diana Danca

Rhiannon Thomas-Tran

Antonio J M Barbosa, Jr

James P Harding

Michael T Tudesco

Soumya Mitra

Jeff A Zablocki

John O Link

Hyung-Jung Pyun

Scott E Lazerwith

Zheng-Yu Yang

Darryl Kato

Sheila M Zipfel

Gregory Notte

Juan A Guerrero

Matthew Ernst Voss

Jiayao Li

Adam James Schrier

Michael Sangi

Ashley Anne Katana

James William Darrow

Gayatri Balan

Gregg M Schwarzwalder

Julie A Di Paolo

Helen Yu

Antonio J Barbosa

Astrid Clarke

Chen Chen

Douglas A I Pippin

Dorothée Saddier Axe

Brian M Weist

Nicholas Mai

James W Darrow

Robert W DeSimone

Joshua A Kaplan

Olaf Kinzel

Claus Kremoser

Joseph Raker

Douglas A Pippin

William Martin Rennells

Morin Mae Frick

Tony Lee

Steven L Gallion

Elizabeth M Horstman

JinMing Xiong

Douglas G Stafford

William M Rennells

Jinming Xiong

Jr Antonio J Barbosa

Robert W Desimone

The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.

FXR (NR1H4) modulating compounds

The present disclosure relates generally to compounds that bind to and act as degraders of an IKAROS Family Zinc Finger (IKZF) protein, such as IKZF2 (Helios) and/or IKZF4 (Eos). The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding and degradation of an IKZF protein, such as IKZF2 and/or IKZF4, including cancer.

IKAROS Zinc Finger Family degraders and uses thereof

The present disclosure relates to compounds that are Syk inhibitors or pharmaceutically acceptable salts or co-crystals thereof, and pharmaceutical compositions thereof, and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, a Syk inhibitor is a crystalline monomesylate salt of 6-(6-aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo-[1,2-a]pyrazin-8-amine of formula 2:

Crystalline succinate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine as a Syk inhibitor

The present disclosure relates to compounds that bind to and act as degraders of an IKAROS Family Zinc Finger (IKZF) protein, such as IKZF2 (Helios). The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding and degradation of an IKZF protein, such as IKZF2, including cancer.

IKAROS zinc finger family degraders and uses thereof

The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), and therapeutic methods for treating inflammatory disease.

Quinoline derivatives

The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), therapeutic methods for treating inflammatory disease.

Compounds for inhibition of &#x3b1;4 &#x3b2;7 integrin

The present disclosure relates to compounds that are Syk inhibitors or pharmaceutically acceptable salts or co-crystals thereof, and pharmaceutical compositions thereof, and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, a Syk inhibitor is a crystalline monomesylate salt of 6-(6-aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo-[1,2-a]pyrazin-8-amine of formula 2: 

Crystalline succinate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine

Compounds for inhibition of alpha 4 beta 7 integrin

The present disclosure relates generally to compounds that bind to FXR and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.

Compounds for inhibition of &#x3b1;4&#x3b2;7 integrin

Imidazopyridine derivatives

Growing community of inventors

North Branford, CT, United States of America

Peter A Blomgren